Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022

  • ID: 3978161
  • Report
  • Region: Global
  • 94 pages
  • P&S Market Research
1 of 3
The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment is expected to witness the fastest growth, a CAGR of 4.3% during the forecast period.

Osteoporosis disease is the most common bone disease occurring due to reduced bone mineral density, thus increasing risk of fractures and fragile bones. It leads to abnormally porous bones such as sponge, which facilitates weakening of bones and painful fracture. Bone mineral density decreases naturally with age, and hence aging population face high risks of osteoporosis. The decline in bone strength is only visible after the bone gets fractured. Most of the spine, hip, shoulder and forearm fractures occur in aged people of 65 years and above. One of the major procedures to build stronger muscle and bones is exercising regularly during the teenage years, which in turn leads to a lower risk of osteoporosis disease. The increasing trend of inactive lifestyle and obesity leads to growing prevalence of osteoporosis disease.

Some of the signs and symptoms of the osteoporosis are falling risk and fractures. Diagnostic tests of osteoporosis include X-Ray test and traditional radiography tests, which is further confirmed with the help of bone density test. Osteoporosis disease can be managed by nutrition emphasis, lifestyle management and medicines. According to National Osteoporosis Foundation, by 2025 osteoporosis would lead to approximately three million fractures.

Based on drug class, the global osteoporosis drugs market has been segmented as bisphosphonates, parathyroid hormone therapy, SERM’s, rank ligand inhibitor, calcitonin, and others. The bisphosphonates segment dominated the global market in 2015.

The global osteoporosis drugs market is growing due to growing geriatric population, increasing prevalence of osteoporosis in postmenopausal women and increasing healthcare expenditure. The increasing focus on research & development of new drugs for treatment of osteoporosis and increasing awareness of osteoporosis are also driving the growth of the global osteoporosis drugs market.

The restraints for the growth of the global osteoporosis drugs market include strict regulatory requirements for the approval of drugs and patent expiry of blockbuster drugs. The side-effects and complications associated with administration of osteoporosis drugs such as nausea, ulcer in stomach and irritable bowel syndrome are also hindering the growth of the global market.

Geographically, North America is expected to continue being the largest market for osteoporosis drugs globally, during 2016-2022. It is due to growing geriatric population and increasing awareness of osteoporosis. The European osteoporosis drugs market is growing at a significant rate mainly due to growing aging population, increasing prevalence of osteoporosis in postmenopausal women and increasing awareness of osteoporosis. However, the Asia-Pacific market of osteoporosis drugs is expected to witness the highest growth during the forecast period. This is due the growing geriatric population, increasing healthcare expenditure, large pool of patients, modifying lifestyle and increasing awareness of osteoporosis in the region.

Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc., and Amgen Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Scope And Methodology
1.1 Market Definition
1.2 Research Scope
1.2.1 Global Osteoporosis Drug Market Breakdown By Drug Type
1.2.2 Global Osteoporosis Drug Market Breakdown By Geography
1.3 Research Methodology And Sources

2. Executive Summary
2.1 Key Findings
2.2 Research Summary

3. Market Outlook
3.1 Introduction
3.1.1 Causes
3.1.2 Signs And Symptoms
3.1.3 Diagnosis
3.1.4 Prevention And Treatment
3.2 Trends In The Global Osteoporosis Drug Market
3.2.1 Increasing Awareness Of Osteoporosis Care
3.3 Factors Driving Growth Of The Market And Its Impact On Market Forecast
3.3.1 Increasing Prevalence Of Osteoporosis
3.3.2 Rapid Urbanization Affecting Bone Health
3.3.3 Increasing Prevalence Of Osteoporosis In Post-Menopausal Women
3.3.4 Increasing Healthcare Expenditure
3.3.5 Growing Geriatric Population
3.3.6 Increasing R&D Investment In Drug Discovery And Development
3.3.7 Impact Analysis Of Drivers On Market Forecast
3.4 Factors Hindering Growth Of The Market And Its Impact On Market Forecast
3.4.1 Side-Effects And Complications Associated With Administration Of Osteoporosis Drug
3.4.2 Patent Expiration Of Osteoporosis Drug
3.4.3 Limited Healthcare Reimbursement
3.4.4 Impact Analysis Of Restraints On Market Forecast

4. Drug Approval Process In U.S. And Europe
4.1 Drug Approval Process In The U.S.
4.2 Drug Approval Process In The Eu

5. Global Osteoporosis Drug Market Size And Forecast (2012-2022)
5.1 Global Osteoporosis Drug Market, By Drug Type
5.2 Global Osteoporosis Drug Market, By Region

6. Global Osteoporosis Drug Market, By Drug Type
6.1 Bisphosphonates Market
6.1.1 Global Bisphosphonates Market, By Region
6.2 Parathyroid Hormone Therapy Market
6.2.1 Global Parathyroid Hormone Therapy Market, By Region
6.3 Calcitonin Market
6.3.1 Global Calcitonin Market, By Region
6.4 Selective Estrogen Receptor Modulator (Serm) Market
6.4.1 Global Serm Market, By Region
6.5 Rank Ligand Inhibitor Market
6.5.1 Global Rank Ligand Inhibitor Market, By Region

7. Global Osteoporosis Drug Market, By Geography
7.1 North America Osteoporosis Drug Market
7.1.1 North America Osteoporosis Drug Market, By Drug Type
7.1.2 North America Osteoporosis Drug Market, By Country
7.2 Europe Osteoporosis Drug Market
7.2.1 Europe Osteoporosis Drug Market, By Drug Type
7.2.2 Europe Osteoporosis Drug Market, By Country
7.3 Asia-Pacific Osteoporosis Drug Market
7.3.1 Asia-Pacific Osteoporosis Drug Market, By Drug Type
7.3.2 Asia-Pacific Osteoporosis Drug Market, By Country
7.4 Row Osteoporosis Drug Market
7.4.1 Row Osteoporosis Drug Market, By Drug Type

8. Competitive Analysis
8.1 Porters Five Forces Of Competitive Position Analysis
8.1.1 Bargaining Power Of Buyers
8.1.2 Bargaining Power Of Suppliers
8.1.3 Threat Of New Entrants
8.1.4 Intensity Of Rivalry
8.1.5 Threat Of Substitutes
8.2 Competitive Positioning Of The Global Osteoporosis Drug Market
8.2.1 Competitive Positioning Of Global Osteoporosis Drug Market, By Drug Type

9. Company Profiles And Strategic Developments
9.1 Key Company Profiles
9.1.1 Pfizer, Inc.
9.1.1.1 Business Overview
9.1.1.2 Product And Service Offerings
9.1.2 Eli Lily And Company
9.1.2.1 Business Overview
9.1.2.2 Product And Service Offerings
9.1.3 F. Hoffmann La Roche
9.1.3.1 Business Overview
9.1.3.2 Product And Service Offerings
9.1.4 Novartis Ag
9.1.4.1 Business Overview
9.1.4.2 Product And Service Offerings
9.1.5 Merck & Co., Inc.
9.1.5.1 Business Overview
9.1.5.2 Product And Service Offerings
9.1.6 Amgen, Inc.
9.1.6.1 Business Overview
9.1.6.2 Product And Service Offerings
9.1.7 Radius Health, Inc.
9.1.7.1 Business Overview
9.1.7.2 Product And Service Offerings
9.1.8 Teva Pharmaceutical Industries Ltd.
9.1.8.1 Business Overview
9.1.8.2 Product And Service Offerings
9.1.9 Glaxosmithkline Plc
9.1.9.1 Business Overview
9.1.9.2 Product And Service Offerings
9.2 Strategic Developments In The Osteoporosis Drug Market
9.2.1 Merger & Acquisition
9.2.2 Collaboration/ Partnership
9.2.3 Product Launch
9.2.4 Others

10. Appendix
10.1 List Of Abbreviations

List Of Tables
Table 1: Specific Primary And Secondary Sources Used For This Publication
Table 2: Global Osteoporosis Drug Market Snapshot
Table 3: T-Score Table
Table 4: Healthcare Expenditure As % Of Gdp
Table 5: Some Of The Osteoporosis Drugs In Pipeline
Table 6: Drivers For The Market: Impact Analysis
Table 7: Restraints For The Market: Impact Analysis
Table 8: Global Osteoporosis Drug Market, By Drug Type, $M (2012-2015)
Table 9: Global Osteoporosis Drug Market, By Drug Type, $M (2016-2022)
Table 10: Global Osteoporosis Drug Market, By Region, $M (2012-2015)
Table 11: Global Osteoporosis Drug Market, By Region, $M (2016-2022)
Table 12: Global Bisphosphonates Market, By Region, $M (2012-2015)
Table 13: Global Bisphosphonates Market, By Region, $M (2016-2022)
Table 14: Global Parathyroid Hormone Therapy Market, By Region, $M (2012-2015)
Table 15: Global Parathyroid Hormone Therapy Market, By Region, $M (2016-2022)
Table 16: Global Calcitonin Market, By Region, $M (2012-2015)
Table 17: Global Calcitonin Market, By Region, $M (2016-2022)
Table 18: Global Serm Market, By Region, $M (2012-2015)
Table 19: Global Serm Market, By Region, $M (2016-2022)
Table 20: Global Rank Ligand Inhibitor Market, By Region, $M (2012-2015)
Table 21: Global Rank Ligand Inhibitor Market, By Region, $M (2016-2022)
Table 22: North America Osteoporosis Drug Market, By Drug Type, $M (2012-2015)
Table 23: North America Osteoporosis Drug Market, By Drug Type, $M (2016-2022)
Table 24: North America Osteoporosis Drug Market, By Country, $M (2012-2015)
Table 25: North America Osteoporosis Durg Market, By Country, $M (2016-2022)
Table 26: Europe Osteoporosis Drug Market, By Drug Type, $M (2012-2015)
Table 27: Europe Osteoporosis Drug Market, By Drug Type, $M (2016-2022)
Table 28: Europe Osteoporosis Drug Market, By Country, $M (2012-2015)
Table 29: Europe Osteoporosis Drug Market, By Country, $M (2016-2022)
Table 30: Asia-Pacific Osteoporosis Drug Market, By Drug Type, $M (2012-2015)
Table 31: Asia-Pacific Osteoporosis Drug Market, By Drug Type, $M (2016-2022)
Table 32: Asia-Pacific Osteoporosis Drug Market, By Country, $M (2012-2015)
Table 33: Asia-Pacific Osteoporosis Drug Market, By Country, $M (2016-2022)
Table 34: Row Osteoporosis Drug Market, By Drug Type, $M (2012-2015)
Table 35: Row Osteoporosis Drug Market, By Drug Type, $M (2016-2022)
Table 36: Pfizer, Inc.-Key Facts
Table 37: Eli Lily And Company-Key Facts
Table 38: F. Hoffmann La Roche-Key Facts
Table 39: Novartis Ag-Key Facts
Table 40: Merck & Co., Inc.-Key Facts
Table 41: Amgen, Inc.-Key Facts
Table 42: Radius Health, Inc.-Key Facts
Table 43: Teva Pharmaceutical Industries Ltd.- Key Facts
Table 44: Glaxosmithkline Plc- Key Facts

List Of Figures
Fig 1: Research Scope For Global Osteoporosis Drug Market
Fig 2: Research Methodology For Global Osteoporosis Drug Market
Fig 3: Comparison Of Normal Bone And The Osteoporotic Bone
Fig 4: Pathogensis Of Osteoporotic Fracture
Fig 5: Some Of The Health Problems And Medical Procedures Leading To Osteoporosis
Fig 6: Preventive Measures For Osteoporosis In Women
Fig 7: Snapshot Of Osteoporosis
Fig 8: Osteoporosis Fracture Worldwide (1990 And 2050)
Fig 9: Role Of Estrogen In Osteoporosis
Fig 10: Aging Population As A Percentage Of Total Population
Fig 11: Global Osteoporosis Drug Market, $M (2012-2022)
Fig 12: Global Osteoporosis Drug Market, By Drug Type, $M (2012-2022)
Fig 13: Global Osteoporosis Drug Market Split, By Drug Type (2015)
Fig 14: Global Osteoporosis Drug Market, By Region, $M (2012-2022)
Fig 15: Global Osteoporosis Drug Market Split, By Region (2015)
Fig 16: Global Bisphosphonates Market, By Region, $M (2012-2022)
Fig 17: Global Parathyroid Hormone Therapy Market, By Region, $M (2012-2022)
Fig 18: Global Calcitonin Market, By Region, $M (2012-2022)
Fig 19: Global Serm Market, By Region, $M (2012-2022)
Fig 20: Global Rank Ligand Inhibitor Market, By Region, $M (2012-2022)
Fig 21: Worldwide Major Markets For Osteoporosis Drug (2022)
Fig 22: North America Osteoporosis Drug Market, By Drug Type, $M (2012-2022)
Fig 23: North America Osteoporosis Drug Market, By Country, $M (2012-2022)
Fig 24: Europe Osteoporosis Drug Market, By Drug Type, $M (2012-2022)
Fig 25: Europe Osteoporosis Drug Market, By Country, $M (2012-2022)
Fig 26: Asia-Pacific Osteoporosis Drug Market, By Drug Type, $M (2012-2022)
Fig 27: Asia-Pacific Osteoporosis Drug Market, By Country, $M (2012-2022)
Fig 28: Row Osteoporosis Drug Market, By Drug Type, $M (2012-2022)
Fig 29: Porter’S Five Forces Of Competitive Position Analysis
Fig 30: Competitive Positioning Of Global Osteoporosis Drug Market, By Drug Type
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll